Descriptive Epidemiology of Hidradenitis Suppurativa in Greece: A Study of 152 Cases

Overview

Journal Skin Appendage Disord

Specialty Dermatology

Date 2017 Nov 28

PMID 29177148

Citations 8

Authors

Alexandros C Katoulis

Aikaterini I Liakou

Nikolaos Rotsiamis

Stefanos Bonovas

Evangelia Bozi

Efstathios Rallis

Christos Christodoulou

Dimitrios Rigopoulos

Affiliations

Soon will be listed here.

Abstract

Background/objective: Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease that remarkably affects the patients' quality of life. A prospective study of 152 HS patients was conducted in order to depict the clinico-epidemiological characteristics of HS patients in Greece.

Materials And Methods: From February 2015 to August 2016, 152 patients attended the Hidradenitis Suppurativa Outpatient Clinic of our department. The most important clinico-epidemiological data of the patients were registered. Descriptive statistics and an ordered logistic regression analysis were performed.

Results: Of the 152 patients, 60.5% were females. Their median age was 37 years. A total of 26.3% of the patients suffered from Hurley stage I, 44.7% from Hurley stage II, and 29.0% from Hurley stage III. The median duration of disease was 9 years. The most common site of involvement was the groins. The mean Dermatology Life Quality Index (DLQI) was higher for Hurley stage III. In multivariable analysis, only the body mass index was found to independently predict the disease severity.

Conclusion: Among the factors examined, the body mass index appears to independently predict the disease severity. Quality of life evaluation revealed a stronger impact compared to the international experience. To our knowledge, this is the first descriptive epidemiological study among HS patients in Greece.

Citing Articles

A Clinicodemographic Study of Indian Patients with Hidradenitis Suppurativa and its Association with Metabolic Syndrome.

De D, Baskaran N, Thakur V, Hanumanthu V, Bakshi S, Bhandari S Indian Dermatol Online J. 2024; 15(6):963-970.

PMID: 39640442 PMC: 11616909. DOI: 10.4103/idoj.idoj_330_24.

Burden of Hidradenitis Suppurativa: A Systematic Literature Review of Patient Reported Outcomes.

Kimball A, Kirby J, Ingram J, Tran T, Pansar I, Ciaravino V Dermatol Ther (Heidelb). 2024; 14(1):83-98.

PMID: 38183616 PMC: 10828455. DOI: 10.1007/s13555-023-01085-w.

A Prospective Observational Study to Evaluate the Factors Affecting the Dermatology Life Quality Index in Patients With Hidradenitis Suppurativa.

Menon A, Gupta P, Suri R, Thakare V, Dubey L, Patil S Cureus. 2023; 15(2):e35510.

PMID: 37007422 PMC: 10050991. DOI: 10.7759/cureus.35510.

Efficacy of Subantimicrobial, Modified-Release Doxycycline Compared to Regular-Release Doxycycline for the Treatment of Hidradenitis Suppurativa.

Kontochristopoulos G, Tsiogka A, Agiasofitou E, Kapsiocha A, Soulaidopoulos S, Liakou A Skin Appendage Disord. 2022; 8(6):476-481.

PMID: 36407641 PMC: 9672876. DOI: 10.1159/000524762.

Transcriptome Meta-Analysis Confirms the Hidradenitis Suppurativa Pathogenic Triad: Upregulated Inflammation, Altered Epithelial Organization, and Dysregulated Metabolic Signaling.

de Oliveira A, Bloise G, Moltrasio C, Coelho A, Agrelli A, Moura R Biomolecules. 2022; 12(10).

PMID: 36291580 PMC: 9599370. DOI: 10.3390/biom12101371.

References

Canoui-Poitrine F, Revuz J, Wolkenstein P, Viallette C, Gabison G, Pouget F . Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity. J Am Acad Dermatol. 2009; 61(1):51-7. DOI: 10.1016/j.jaad.2009.02.013. View

Jemec G . The symptomatology of hidradenitis suppurativa in women. Br J Dermatol. 1988; 119(3):345-50. DOI: 10.1111/j.1365-2133.1988.tb03227.x. View

Fabbrocini G, De Vita V, Donnarumma M, Russo G, Monfrecola G . South Italy: A Privileged Perspective to Understand the Relationship between Hidradenitis Suppurativa and Overweight/Obesity. Skin Appendage Disord. 2016; 2(1-2):52-56. PMC: 5096266. DOI: 10.1159/000447716. View

Matusiak L, Bieniek A, Szepietowski J . Hidradenitis suppurativa and associated factors: still unsolved problems. J Am Acad Dermatol. 2009; 61(2):362-5. DOI: 10.1016/j.jaad.2009.03.043. View

Girouard S, Falk R, Rennke H, Merola J . Hidradenitis suppurativa resulting in systemic amyloid A amyloidosis: a case report and review of the literature. Dermatol Online J. 2012; 18(1):2. View

Fimmel S, Zouboulis C . Comorbidities of hidradenitis suppurativa (acne inversa). Dermatoendocrinol. 2011; 2(1):9-16. PMC: 3084959. DOI: 10.4161/derm.2.1.12490. View

Scheinfeld N . Hidradenitis Suppurativa in prepubescent and pubescent children. Clin Dermatol. 2015; 33(3):316-9. DOI: 10.1016/j.clindermatol.2014.12.007. View

Davis S, Lin H, Balkrishnan R, Feldman S . Hidradenitis Suppurativa Management in the United States: An Analysis of the National Ambulatory Medical Care Survey and MarketScan Medicaid Databases. Skin Appendage Disord. 2016; 1(2):65-73. PMC: 4857854. DOI: 10.1159/000431037. View

Onderdijk A, van der Zee H, Esmann S, Lophaven S, Dufour D, Jemec G . Depression in patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2012; 27(4):473-8. DOI: 10.1111/j.1468-3083.2012.04468.x. View

10.

Esmann S, Jemec G . Psychosocial impact of hidradenitis suppurativa: a qualitative study. Acta Derm Venereol. 2011; 91(3):328-32. DOI: 10.2340/00015555-1082. View

11.

Tennant Jr F, BERGERON J, Stone O, Mullins J . Anemia associated with hidradenitis suppurativa. Arch Dermatol. 1968; 98(2):138-40. View

12.

Revuz J, Canoui-Poitrine F, Wolkenstein P, Viallette C, Gabison G, Pouget F . Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol. 2008; 59(4):596-601. DOI: 10.1016/j.jaad.2008.06.020. View

13.

Cosmatos I, Matcho A, Weinstein R, Montgomery M, Stang P . Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. J Am Acad Dermatol. 2012; 68(3):412-9. DOI: 10.1016/j.jaad.2012.07.027. View

14.

Lapins J, Ye W, Nyren O, Emtestam L . Incidence of cancer among patients with hidradenitis suppurativa. Arch Dermatol. 2001; 137(6):730-4. View

15.

Jemec G, Heidenheim M, Nielsen N . The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol. 1996; 35(2 Pt 1):191-4. DOI: 10.1016/s0190-9622(96)90321-7. View

16.

Deckers I, Janse I, van der Zee H, Nijsten T, Boer J, Horvath B . Hidradenitis suppurativa (HS) is associated with low socioeconomic status (SES): A cross-sectional reference study. J Am Acad Dermatol. 2016; 75(4):755-759.e1. DOI: 10.1016/j.jaad.2016.04.067. View

17.

Fitzsimmons J, Guilbert P, Fitzsimmons E . Evidence of genetic factors in hidradenitis suppurativa. Br J Dermatol. 1985; 113(1):1-8. DOI: 10.1111/j.1365-2133.1985.tb02037.x. View

18.

Sartorius K, Emtestam L, Jemec G, Lapins J . Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol. 2009; 161(4):831-9. DOI: 10.1111/j.1365-2133.2009.09198.x. View

19.

Wolkenstein P, Loundou A, Barrau K, Auquier P, Revuz J . Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J Am Acad Dermatol. 2006; 56(4):621-3. DOI: 10.1016/j.jaad.2006.08.061. View

20.

Ulrich A, Hildebrandt U, Ulrich J . [Acne inversa: influence of associated factors in the extent of the disease and the result of surgery]. Hautarzt. 2014; 65(7):623-7. DOI: 10.1007/s00105-014-2839-7. View